Cargando…
Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation
Eukaryotic elongation factor 2 kinase (eEF2K) is a highly conserved α kinase and is increasingly considered as an attractive therapeutic target for cancer as well as other diseases. However, so far, no selective and potent inhibitors of eEF2K have been identified. In this study, pharmacophore screen...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369671/ https://www.ncbi.nlm.nih.gov/pubmed/35956836 http://dx.doi.org/10.3390/molecules27154886 |
_version_ | 1784766537325871104 |
---|---|
author | Fu, Qinghua Liu, Xiaomei Li, Yan Wang, Peng Wu, Tian Xiao, Haihan Zhao, Yameng Liao, Qichao Song, Ziyi |
author_facet | Fu, Qinghua Liu, Xiaomei Li, Yan Wang, Peng Wu, Tian Xiao, Haihan Zhao, Yameng Liao, Qichao Song, Ziyi |
author_sort | Fu, Qinghua |
collection | PubMed |
description | Eukaryotic elongation factor 2 kinase (eEF2K) is a highly conserved α kinase and is increasingly considered as an attractive therapeutic target for cancer as well as other diseases. However, so far, no selective and potent inhibitors of eEF2K have been identified. In this study, pharmacophore screening, homology modeling, and molecular docking methods were adopted to screen novel inhibitor hits of eEF2K from the traditional Chinese medicine database (TCMD), and then cytotoxicity assay and western blotting were performed to verify the validity of the screen. Resultantly, after two steps of screening, a total of 1077 chemicals were obtained as inhibitor hits for eEF2K from all 23,034 compounds in TCMD. Then, to verify the validity, the top 10 purchasable chemicals were further analyzed. Afterward, Oleuropein and Rhoifolin, two reported antitumor chemicals, were found to have low cytotoxicity but potent inhibitory effects on eEF2K activity. Finally, molecular dynamics simulation, pharmacokinetic and toxicological analyses were conducted to evaluate the property and potential of Oleuropein and Rhoifolin to be drugs. Together, by integrating in silico screening and in vitro biochemical studies, Oleuropein and Rhoifolin were revealed as novel eEF2K inhibitors, which will shed new lights for eEF2K-targeting drug development and anticancer therapy. |
format | Online Article Text |
id | pubmed-9369671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93696712022-08-12 Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation Fu, Qinghua Liu, Xiaomei Li, Yan Wang, Peng Wu, Tian Xiao, Haihan Zhao, Yameng Liao, Qichao Song, Ziyi Molecules Article Eukaryotic elongation factor 2 kinase (eEF2K) is a highly conserved α kinase and is increasingly considered as an attractive therapeutic target for cancer as well as other diseases. However, so far, no selective and potent inhibitors of eEF2K have been identified. In this study, pharmacophore screening, homology modeling, and molecular docking methods were adopted to screen novel inhibitor hits of eEF2K from the traditional Chinese medicine database (TCMD), and then cytotoxicity assay and western blotting were performed to verify the validity of the screen. Resultantly, after two steps of screening, a total of 1077 chemicals were obtained as inhibitor hits for eEF2K from all 23,034 compounds in TCMD. Then, to verify the validity, the top 10 purchasable chemicals were further analyzed. Afterward, Oleuropein and Rhoifolin, two reported antitumor chemicals, were found to have low cytotoxicity but potent inhibitory effects on eEF2K activity. Finally, molecular dynamics simulation, pharmacokinetic and toxicological analyses were conducted to evaluate the property and potential of Oleuropein and Rhoifolin to be drugs. Together, by integrating in silico screening and in vitro biochemical studies, Oleuropein and Rhoifolin were revealed as novel eEF2K inhibitors, which will shed new lights for eEF2K-targeting drug development and anticancer therapy. MDPI 2022-07-30 /pmc/articles/PMC9369671/ /pubmed/35956836 http://dx.doi.org/10.3390/molecules27154886 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fu, Qinghua Liu, Xiaomei Li, Yan Wang, Peng Wu, Tian Xiao, Haihan Zhao, Yameng Liao, Qichao Song, Ziyi Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation |
title | Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation |
title_full | Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation |
title_fullStr | Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation |
title_full_unstemmed | Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation |
title_short | Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation |
title_sort | discovery of new inhibitors of eef2k from traditional chinese medicine based on in silico screening and in vitro experimental validation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369671/ https://www.ncbi.nlm.nih.gov/pubmed/35956836 http://dx.doi.org/10.3390/molecules27154886 |
work_keys_str_mv | AT fuqinghua discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation AT liuxiaomei discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation AT liyan discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation AT wangpeng discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation AT wutian discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation AT xiaohaihan discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation AT zhaoyameng discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation AT liaoqichao discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation AT songziyi discoveryofnewinhibitorsofeef2kfromtraditionalchinesemedicinebasedoninsilicoscreeningandinvitroexperimentalvalidation |